The study revealed a regulation model based on ERK1/2, suggesting that ERK1/2 signaling pathway may be an important control link for mitigation of hypertrophic cardiomyopathy treatment. This evidence concerns the gene MAPK3 and hypertrophic cardiomyopathy.